16 July 2019

NICE, 10 Spring Gardens, London, SW1A 2BU

Final Agenda 

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00.

Please note that this agenda is final but is subject to change before the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Minutes from the last Committee meeting held on Thursday 13 June 2019 – Part 1 only (open session)
  5. Appraisal of Neratinib for treating early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab - [ID981]
    • 5.1. Declarations of interest – Part 1 only (open session)
    • 5.2. Introduction by the Chair, Dr Jane Adam – Part 1 only (open session)
    • 5.3. Presentation by the Lead team – Part 1 AND part 2 (open and closed session)
    • 5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of Rucaparib for maintenance treatment of recurrent platinum-sensitive epithelial ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy - [ID1485] 
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by the Chair, Dr Jane Adam Part 1 only (open session)
    • 6.3. Presentation by the Lead Team – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (including a review of technology appraisal no. 381) [ID1296] 
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by the Chair, Dr Jane Adam  Part 1 only (open session)
    • 7.3. Presentation by the Chair, Dr Jane Adam – Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
     

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

To be confirmed. 

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Tuesday 2 July 2019 for Neratinib and Rucaparib and on Tuesday 9 July 2019 for OlaparibPlease note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Ingrid Temmerman.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 18 June 2019 to 09 July 2019
Registration is closed.